LNSR - LENSAR Inc

https://www.lensar.com

Strong Sell Momentum: Bearish

Recent News

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - LENSAR ( NASDAQ:LNSR )

Benzinga • 2 months, 1 week ago • score: 0.34

ORLANDO, Fla., July 01, 2025 ( GLOBE NEWSWIRE ) -- LENSAR, Inc. LNSR ( "LENSAR" or the "Company" ) today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units ( "RSUs" ) .

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.

52W High

$17.31

52W Low

$3.80

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.49

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.05

EV/Revenue (<3 favorable)

2.18

P/S (TTM) (<3 favorable)

2.49

P/B (<3 favorable)

2.17

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

19.41%

Institutions (25–75% balanced)

47.84%

Shares Outstanding

11,934,800

Float

8,637,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

58,364,000

Gross Profit (TTM)

27,523,000

EPS (TTM)

-4.21

Profit Margin (>10% good)

-0.85%

Operating Margin (TTM) (higher better)

-0.15%

ROE (TTM) (>15% strong)

-3.50%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.10

Momentum

Bearish momentum

Value

-0.1728

-0.2136

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025